RNA therapeutics developer Silence Therapeutics announced on Monday that its chief executive Ali Mortazavi will leave the company with immediate effect after a six year stay.
RNA-based therapeutics discovery and development company Silence Therapeutics has sold a further part of its holding of common shares in Arrowhead Pharmaceuticals, it announced on Monday.
Serious disease treatment developer Silence Therapeutics has sold part of its holding of common shares in Arrowhead Pharmaceuticals, it announced on Monday.
Silence Therapeutics updated the market on its ongoing litigation matters on Friday, having previously delivered its claim for declaratory relief relating to its entitlement to Supplementary Protection Certificates (SPCs) on certain Alnylam products.
Silence Therapeutics announced what it called a "further step" in the expansion of its chemical modification patent estate on Monday, with the US Patent and Trademark Office issuing a notice of allowance for US patent application 15/589971.
Serious disease treatment developer Silence Therapeutics updated the market on one of its patent-protected products on Monday, noting a release from Alnylam Pharmaceuticals on Friday which stated it was working with Sanofi Genzyme to initiate a phase 3 programme for the investigational 'fitusiran' treatment in patients with hemophilia A and B, with or without inhibitors.
Developer of novel RNA therapeutics for the treatment of serious disease, Silence Therapeutics, announced a "further step" in the expansion of its chemical modification patent estate.
Biotechnology company Silence Therapeutics says 2016 was a year of transition for the company and RNA interference (RNAi), as it posted a wider full-year pre-tax loss.
Discoverer, deliverer and developer of novel RNA therapeutics for the treatment of serious diseases, Silence Therapeutics updated the market on its announcement on 9 January regarding the acquisition of a minority stake in Arrowhead Pharmaceuticals.
Silence Therapeutics, a developer of ribonucleic acid (RNA) treatments, has bought an 8.4% stake in Nasdaq-listed Arrowowhead Pharmaceuticals for $7.8m ($9.6m).
Silence Therapeutics said it has reached a settlement in the arbitration process with Quark Pharmaceuticals, with the former to receive a $1m cash payment.
A round-up of the biggest director deals today so far.
Biotech company Silence Therapeutics increased research and development spending in 2013 and is now quite confident of completing a 'substantive' fundraising.
Aberdeen Asset Management: Goldman Sachs lowers target price from 600p to 540p, while its buy recommendation is kept.